BioMarin seeks haemophilia gene therapy approval after promising dataBioMarin is set to file for approval for its haemophilia gene therapy valoctocogene roxaparvovec, after it achieved pre-specified Share XBioMarin seeks haemophilia gene therapy approval after promising datahttps://pharmaphorum.com/news/biomarin-seeks-haemophilia-gene-therapy-approval-after-promising-data/
The unmet needs of bleeding disorder patientsAhead of eyeforpharma Philadelphia 2019, we talk to speaker and haemophilia advocate Michelle Rice about the changing landscape Share XThe unmet needs of bleeding disorder patientshttps://pharmaphorum.com/views-analysis-patients/the-unmet-needs-of-bleeding-disorder-patients/
EU expands use of Roche’s new haemophilia A drugThe European Commission has approved Roche haemophilia A drug Hemlibra for patients without factor VIII inhibitors, expanding the Share XEU expands use of Roche’s new haemophilia A drughttps://pharmaphorum.com/news/eu-expands-use-of-roches-new-haemophilia-a-drug/
Gene therapy firm BioMarin stages haemophilia musicalBioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression Share XGene therapy firm BioMarin stages haemophilia musicalhttps://pharmaphorum.com/news/gene-therapy-firm-biomarin-stages-haemophilia-musical/
How pharma can boost engagement by embracing support networksConnecting with patients has become a central plank in the pharma marketing playbook, but should companies be looking Share XHow pharma can boost engagement by embracing support networkshttps://pharmaphorum.com/patients/insights-patients/how-pharma-can-boost-engagement-by-embracing-support-networks/
Roche’s Hemlibra approved in expanded haemophilia A useRoche’s Hemlibra has been approved in an expanded use in haemophilia A in the US, as the Swiss Share XRoche’s Hemlibra approved in expanded haemophilia A usehttps://pharmaphorum.com/news/roches-hemlibra-approved-in-expanded-haemophilia-a-use/
Sanofi’s rare disease drug Cablivi approved in the EUThe European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired Share XSanofi’s rare disease drug Cablivi approved in the EUhttps://pharmaphorum.com/news/sanofi-cablivi-approved-europe/
Roche reveals haemophilia drug data ahead of label expansion decisionRoche has revealed new trial data that make the case for use of its haemophilia A drug Hemlibra Share XRoche reveals haemophilia drug data ahead of label expansion decisionhttps://pharmaphorum.com/news/roche-reveals-hemlibra-drug-data-ahead-expansion-decision/
Pfizer moves haemophilia gene therapy into phase 3US pharma giant Pfizer and partner Spark Therapeutics has begun a phase 3 trial of a gene therapy Share XPfizer moves haemophilia gene therapy into phase 3https://pharmaphorum.com/r-d/pfizer-haemophilia-b-gene-therapy/
